
NeuroPace Unveils RNS System Enhancements to Improve Care for Epilepsy Patients
NeuroPace, Inc. (Nasdaq: NPCE) has announced a range of significant enhancements to its RNS System, aimed at simplifying care for patients battling drug-resistant focal epilepsy. These innovations, including the nSight Platform, Simple Set Programming, and the Tablet Remote Monitor, are designed to enhance the overall experience with the RNS System for both healthcare providers and patients, ultimately resulting in improved patient care.
The RNS System is distinguished as the only commercially available closed-loop system designed to treat drug-resistant focal epilepsy. By continuously monitoring brain activity, it can detect abnormal patterns and respond to them before they lead to clinical seizures. The RNS System then records these events, providing clinicians with valuable data to actively manage patient care. In a large multicenter prospective study, the system has been shown to reduce seizures by 82% at three years in epilepsy patients.
In August, the company introduced the next generation of its nSight Platform, an online portal that offers a secure and simplified experience with RNS System data. One of its key components is the Patient nSight Report, which allows physicians to efficiently review patient data through a customized report. This report consolidates information from various sources, including digital seizure diaries, and provides an overview of intracranial electroencephalography (iEEG) details and historical data trends. This information can assist physicians in identifying patient-specific insights for optimizing care, including behavioral counseling and programming changes.
Furthermore, the recently FDA-approved Tablet Remote Monitor (TRM) simplifies the way patients interact with NeuroPace’s RNS System. The TRM transfers iEEG data captured by the patient’s RNS System to their clinician, facilitating monitoring, assessment, and treatment guidance. The TRM offers a smaller, more portable profile with a user-friendly interface and wireless connectivity. Patient data is wirelessly transferred from the RNS Neurostimulator to the TRM, where it is uploaded to a secure database for later review by the patient’s clinician. The TRM is expected to be commercially launched in the fourth quarter of 2023 following regulatory approval.
Joel Becker, CEO of NeuroPace, highlighted the company’s commitment to making it easier for clinicians to provide patient care efficiently. He emphasized that the RNS System not only focuses on clinical superiority but also aims to facilitate streamlined care, especially in the community setting. These enhancements demonstrate the company’s dedication to improving patient outcomes and quality of life. The team’s continuous work on the RNS System aims to deliver a product that excels in both outcomes and ease of use.